Cullinan Therapeutics Inc (NASDAQ: CGEM) kicked off on Friday, down -6.82% from the previous trading day, before settling in for the closing price of $12.90. Over the past 52 weeks, CGEM has traded in a range of $9.55-$30.19.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
During the last 5-year period, the sales drop of Healthcare Sector giant was -20.00%. While this was happening, its average annual earnings per share was recorded 17.66%. With a float of $37.06 million, this company’s outstanding shares have now reached $58.14 million.
Let’s determine the extent of company efficiency that accounts for 85 employees. In terms of profitability, gross margin is 0.0%, operating margin of 0.0%, and the pretax margin is 0.0%.
Cullinan Therapeutics Inc (CGEM) Breakdown of a Key Holders of the stock
Our next focus will be how large-scale investors are participating in this stock of the Biotechnology Industry. The insider ownership of Cullinan Therapeutics Inc is 36.36%, while institutional ownership is 77.32%. The most recent insider transaction that took place on Dec 24 ’24, was worth 99,708. In this transaction President and CEO of this company sold 8,400 shares at a rate of $11.87, taking the stock ownership to the 263,150 shares. Before that another transaction happened on Dec 18 ’24, when Company’s Chief Scientific Officer sold 4,693 for $11.41, making the entire transaction worth $53,547. This insider now owns 99,760 shares in total.
Cullinan Therapeutics Inc (CGEM) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.84 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around 17.66% per share during the next fiscal year.
Cullinan Therapeutics Inc (NASDAQ: CGEM) Trading Performance Indicators
Take a look at Cullinan Therapeutics Inc’s (CGEM) current performance indicators. Last quarter, stock had a quick ratio of 24.46.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is -2.88, a number that is poised to hit -0.79 in the next quarter and is forecasted to reach -3.17 in one year’s time.
Technical Analysis of Cullinan Therapeutics Inc (CGEM)
Looking closely at Cullinan Therapeutics Inc (NASDAQ: CGEM), its last 5-days average volume was 0.78 million, which is a jump from its year-to-date volume of 0.65 million. As of the previous 9 days, the stock’s Stochastic %D was 84.62%. Additionally, its Average True Range was 0.81.
During the past 100 days, Cullinan Therapeutics Inc’s (CGEM) raw stochastic average was set at 16.72%, which indicates a significant decrease from 50.00% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 60.12% in the past 14 days, which was higher than the 56.11% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $14.00, while its 200-day Moving Average is $17.76. However, in the short run, Cullinan Therapeutics Inc’s stock first resistance to watch stands at $12.66. Second resistance stands at $13.31. The third major resistance level sits at $13.73. If the price goes on to break the first support level at $11.59, it is likely to go to the next support level at $11.17. Now, if the price goes above the second support level, the third support stands at $10.52.
Cullinan Therapeutics Inc (NASDAQ: CGEM) Key Stats
The company with the Market Capitalisation of 652.15 million has total of 58,228K Shares Outstanding. Its annual sales at the moment are 0 K in contrast with the sum of -153,160 K annual income. Company’s last quarter sales were recorded 0 K and last quarter income was -40,560 K.
